Study suggests immunosuppressive drugs do not contribute to severity of COVID-19
Findings contribute to a growing body of evidence that may provide reassurance to clinicians and patients using chronic immunosuppressive medications By Bloomberg School of Public Health staff report / Published Jan 13, 2021
People taking immunosuppressive drugs to prevent organ transplant rejection or to treat inflammatory or autoimmune diseases do not fare worse than others on average when they are hospitalized with COVID-19, according to a new study from researchers at the Johns Hopkins Bloomberg School of Public Health.
Estimates suggest that there are approximately 10 million immunocompromised people in the U.S. alone. Suppression of the immune system has been considered a potentially major risk factor for severe and fatal COVID-19 because it could allow the SARS-CoV-2 virus to spread unchecked in the body. At the same time, there have been anecdotal
Patients taking immunosuppressive drugs did not have worse COVID-19 outcomes
People taking immunosuppressive drugs to prevent organ transplant rejection or to treat inflammatory or autoimmune diseases do not fare worse than others on average when they are hospitalized with COVID-19, according to a study from researchers at the Johns Hopkins Bloomberg School of Public Health.
Estimates suggest that there are approximately 10 million immunocompromised people in the U.S. alone. Suppression of the immune system has been considered a potentially major risk factor for severe and fatal COVID-19 because it could allow the SARS-CoV-2 virus to spread unchecked in the body.